Life Spine announced today that the US Food and Drug Administration (FDA) has provided additional 510(k) market clearance for the ProLift expandable spacer system.
“The new 8–10mm widths of the ProLift expandable spacer system are essential additions to our innovative Micro Invasive portfolio. The new sizes will more than double our current footprint options for ProLift which will allow us to accommodate a wider range of patients and their unique pathologies,” said Mariusz Knap, vice president of Marketing and Business Development for Life Spine.
He continued: “As with our other expandable devices, the new ProLift additions can be post-packed in situ and feature our proprietary OSSEO-LOC surface technology with 400–600 microns of porosity creating an environment for potential bone on-growth.”
As opposed to traditional static interbodies, ProLift was engineered to reduce the need for surgical steps, such as sequential trialling, and in turn reduce operating time. Additionally, the new smaller widths are designed to decrease patient trauma through smaller incisions and less retraction. The system offers streamlined and intuitive instrumentation and is complemented by Life Spine’s full suite of PLIF and TLIF access, disc preparation and posterior fixation.